Opus Genetics Completes Dosing in Cohort 2 of Phase 1/2 Clinical Trial of OPGx-BEST1 Gene Therapy for Inherited Retinal Diseases

GlobeNewswire Inc. | Nov 5, 2026 7:00 AM EST